Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18

 Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18

Shots:

  • The P-III COMBI-AD trial involves assessing of Tafinlar (150mg bid) + Mekinist (2mg qd) vs PBO in 438 patients with BRAF V600-mutant stage III Melanoma for 44 months and 42 months respectively
  • During the extended follow-up cure rate was 54% vs 37%
  • P-III COMBI-AD trial results: RFS rate @ 44 &42 mos. (59%, 54% vs 40%, 38%); patients with no relapse (54% vs 37%); risk of disease recurrence or death by 53%. RFS@ 1, 2, 3, 4yrs., (88%, 67%, 59%, 54% vs 56%, 44%, 40%, 38%) respectively
  • Tafinlar + Mekinist used for targeting multiple kinases in serine/threonine kinase family-BRAF & MEK1/2 and the combination is currently approved in 60 countries 

Click here to read full press release/ article | Ref: Novartis | Image: Financial Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post